Advice - Extension of reimbursement conditions for solriamfetol (Sunosi®)
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to extend the List 2 conditions for solriamfetol (Sunosi®) to include certain adult patients with obstructive sleep apnoea (OSA). This medicine has been reimbursed for patients with narcolepsy since 1 March 2023. Solriamfetol is already included in the Medicine Reimbursement System (GVS) with further conditions for reimbursement. If the Minister adopts our advice, these reimbursement conditions will be extended.
Solriamfetol is intended for certain adult patients with narcolepsy or OSA
Solriamfetol is the active substance. The brand name is Sunosi®. The medicine can be used to improve wakefulness and reduce excessive daytime sleepiness in adult patients with:
- narcolepsy (with or without cataplexy), the medical term for a sleep disorder that makes people fall asleep suddenly and have uncontrollable sleep attacks, even after adequate sleep; or
- obstructive sleep apnoea (whose EDS has not been adequately treated with primary OSA therapy, such as continuous positive airway pressure (CPAP). This is the medical term for a sleeping disorder in which patients experience repeated short-term occlusions of the trachea (respiratory stops) during sleep.
Advice from the National Health Care Institute on extension of the reimbursement conditions for solriamfetol
The National Health Care Institute advises the Minister of Health, Welfare and Sport to extend the reimbursement conditions for solriamfetol (Sunosi®) for patients with OSA. These are the so-called List 2 conditions.
For more information on the GVS and the Lists 1A, 1B and 2, see page ‘Reimbursement of extramural drugs (GVS)’.
Extension of conditions for reimbursement of solriamfetol
Since 1 March 2023, solriamfetol has been included in the GVS for patients with narcolepsy. With the advice of 16 February 2024, we advise the Minister to extend the List 2 conditions for the indication OSA as follows:
More information or questions?
If you have any questions about this advice, please send your question to the National Health Care Institute via warcg@zinl.nl. If you have questions about the reimbursement of a medicinal product, personal expenses or whether you should pay a contribution, please contact your health insurance provider.
How did the advice come about?
The Scientific Advisory Board (WAR) advises the National Health Care Institute about the assessment. Based on the assessment, the National Health Care Institute sends an advisory report to the Minister of Health, Welfare and Sport. The Minister makes the final decision whether or not to reimburse the medication from the basic health care package.